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Abstract Our previous study has shown that lipophilic 3-hy-
droxy-3-methyl-glutaryl coenzyme A reductase inhibitors of sta-
tins can inhibit interferon-Q-induced inducible nitric oxide syn-
thase gene expression in RAW264.7 macrophages. In this study,
we showed that lovastatin and £uvastatin are able to upregulate
the mRNA expression of the suppressor of cytokine signaling-3
(SOCS-3) gene. This e¡ect is speci¢c for SOCS-3 and could be
blocked by mevalonate, farnesyl pyrophosphate and geranylger-
anyl pyrophosphate, while it was not a¡ected by inhibitors of
protein kinase C and A, mitogen-activated protein/extracellular
signal-regulated kinase kinase, p38 mitogen-activated protein
kinase, c-Jun N-terminal kinase, Src, Raf and Rho kinase.
SOCS-3 expression results in the inhibition of interferon-Q-,
interleukin-6- and macrophage colony-stimulating factor-elicited
signal transducer and activator of transcription phosphorylation,
suggesting a novel anti-in£ammatory mechanism of statins to
down-modulate the functions of interferon-Q-activated macro-
phages.
2 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Signal transducer and activator of transcription (STAT)
proteins are a family of latent transcription factors that are
produced in many cell types and become activated by tyrosine
phosphorylation and dimerization in response to a wide vari-
ety of extracellular cytokines and growth factors [1,2]. This
rapid membrane-to-nucleus signaling system accounts for the
fundamental e¡ects of cytokines in proliferation, di¡erentia-
tion, survival, in£ammation and immunity. The suppressor of
cytokine signaling (SOCS) proteins are a growing family of
suppressor of cytokine signaling molecules that are feedback
inhibitors of cytokine signaling pathways [3^6]. The SOCS
proteins act as negative regulators of the Janus kinase
(JAK)-STAT pathway either by binding and inhibiting JAK
tyrosine kinases or by inhibiting binding of STAT factors to
the cytoplasmic domains of the respective receptors [3,4,7].
Not only do they uncouple the STAT pathway, SOCSs play
an important role in terminating the in£ammatory response to
lipopolysaccharide (LPS) [8^10] and tumor necrosis factor-K
[11].
SOCS proteins can be positively induced through cytokine-
elicited STAT signaling [12]. Evidence suggests that multiple
signal pathways except JAK-STAT are involved in the tran-
scriptional regulation of SOCS. These involve the actions of
LPS [13^16], tumor necrosis factor-K [14], interleukin (IL)-1
[17], phorbol 13-myristate 12-acetate, basic ¢broblast growth
factor [18] and bacterial CpG-DNA [19]. In this context,
SOCS-3 expression can be induced by di¡erent mechanisms,
particularly of extracellular signal-regulated kinase (ERK)
and p38 mitogen-activated protein kinase (MAPK) [14,18,19].
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coen-
zyme A (HMG-CoA) reductase and are widely used as lipid-
lowering agents [20]. Besides the therapeutic use in hyperlip-
idemia, the anti-in£ammatory and immunomodulatory bene-
¢ts of statins have been recently reported in many aspects,
although its mechanisms are not yet completely de¢ned [21].
Most identi¢ed anti-in£ammatory bene¢ts of statins rely on
the reduction of cellular levels of mevalonate, the direct prod-
uct of HMG-CoA reductase, and mevalonate-derived isopre-
noids (farnesyl pyrophosphate (FPP) and geranylgeranyl py-
rophosphate (GGPP), which are involved in post-translational
modi¢cation of several small G proteins, such as Rho, Rac,
Cdc42 and Ras [22,23]. Several studies have shown the abil-
ities of statins to inhibit the immunological functions of in-
terferon-Q (IFN-Q) [21,24,25]. In our previous study, we found
that statins are able to inhibit inducible nitric oxide synthase
(NOS) gene expression caused by IFN-Q in murine RAW264.7
macrophages. This action of statins is attributed to the rapid
interruption of STAT-1 phosphorylation at tyrosine 701 [26].
Since the understanding and evaluation of the pharmacolog-
ical e¡ects of statins are increasing and accelerating their clin-
ical importance and validity, in this study we further explore
the mechanism by which statins uncouple JAK-STAT signal-
ing of cytokines.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM), fetal bovine serum,
penicillin, and streptomycin were obtained from Gibco BRL (Grand
Island, NY, USA). Rabbit polyclonal antibodies against active STAT-
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1 (Y701), STAT-3 (Y705), and STAT-5 (Y694) were purchased from
New England Biolabs (Beverly, MA USA). Rabbit polyclonal anti-
bodies speci¢c for SOCS-1, -2, 3, -5, -6, STAT-1, -3, -5, and L-actin
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). IFN-Q, IL-6, and macrophage colony-stimulating factor
(M-CSF) were purchased from RpD (Minneapolis, MN, USA).
Horseradish peroxidase-coupled anti-rabbit antibody, and the ECL
detection agent were purchased from Amersham Biosciences (Piscat-
away, NJ, USA). Lovastatin, mevalonate, FPP, GGPP, KT5720 and
GW5074 were purchased from Sigma Aldrich (St. Louis, MO, USA).
PD98059, PP2, SB203580, Ro318220, GF109203X, herbimycin A,
Y27632, and FPT inhibitors (FPTI) were purchased from Calbiochem
(San Diego, CA, USA). Fluvastatin and pravastatin were respectively
provided by Novartis (Basel, Switzerland) and Sankyo (Tokyo, Ja-
pan). All materials for sodium dodecyl sulfate^polyacrylamide gel
electrophoresis were obtained from Bio-Rad Laboratories (Hercules,
CA, USA).
2.2. Cell culture
Murine RAW264.7 macrophages obtained from the American Type
Culture Collection (Manassas, VA, USA) were grown at 37‡C in 5%
CO2 using DMEM containing 10% fetal bovine serum, 100 U/ml
penicillin, and 100 Wg/ml streptomycin.
2.3. Immunoblotting analysis
Immunoblotting analysis was performed as in our previous study
[26]. Equal protein levels of cell lysates were denatured in sodium
dodecyl sulfate (SDS), electrophoresed on SDS/polyacrylamide gel,
and transferred to a nitrocellulose membrane. Non-speci¢c binding
was blocked with TBST containing 5% non-fat milk. After incubation
with the appropriate ¢rst antibodies, membranes were washed three
times with TBST. The secondary antibody was incubated for 1 h.
Following three washes with TBST, the protein bands were detected
with the ECL reagent.
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
To amplify SOCS-3 mRNA, macrophages were homogenized in
RNAzol B reagent, and total RNA was extracted by acid guanidi-
nium thiocyanate^phenol^chloroform extraction. RT was performed
using a StrataScript RT-PCR kit following the manufacturer’s recom-
mended procedures. RT-generated cDNAs encoding SOCS-3 and L-
actin genes were ampli¢ed using PCR. The oligonucleotide primers
used corresponded to SOCS-3 (5P-GGA CCA GCG CCA CTT CTT
CAC-3P and 5P-TAC TGG TCC AGG AAC TCC CGA-3P) and
mouse L-actin (5P-GAC TAC CTC ATG AAG ATC CT-3P and 5P-
CCA CAT CTG CTG GAA GGT GG-3P). PCR was performed as
follows: initial denaturing for 2 min at 94‡C, 35 cycles of ampli¢ca-
tion (94‡C for 45 s, 58‡C for 45 s, and 72‡C for 2 min), and 10 min
extension at 72‡C. PCR products were analyzed on 2% agarose gels.
The mRNA of L-actin served as an internal control for sample load-
ing.
3. Results
3.1. Statins selectively induced SOCS-3 gene expression in
RAW264.7 macrophages
Immunoblotting analysis with SOCS-3 antibody indicated
that after 24 h incubation lovastatin and £uvastatin could
increase SOCS-3 protein level (Fig. 1A). The e¡ect of lova-
statin displayed a concentration dependence in the range of
0.1^30 WM. Fluvastatin at concentrations in the range of 3^30
WM caused a similar extent of SOCS-3 induction as 10 WM
lovastatin. In contrast, pravastatin did not induce such an
e¡ect at 30 WM. The stimulatory e¡ect of lovastatin (10
WM) occurred at 12 h incubation and became obvious after
24 h incubation (Fig. 1B). In contrast, LPS (0.1 Wg/ml)-in-
duced SOCS-3 expression began at 3 h, and became promi-
nent at 6 h (Fig. 1B). To extend the understanding of the
e¡ects on other SOCS members, we also determined SOCS-
1, -2, -5, and -6. However, unlike the upregulation of SOCS-3,
lovastatin and £uvastatin at 30 WM did not a¡ect these pro-
tein levels after 24 h treatment (Fig. 2). Of these SOCSs, only
SOCS-1 and -2 can be upregulated by LPS.
To understand whether the e¡ect of statins is dependent on
gene transcription, we performed RT-PCR and found that the
steady-state level of SOCS-3 mRNA was time-dependently
increased by both lovastatin and £uvastatin (Fig. 3).
3.2. SOCS-3 induction by statin is dependent on protein
isoprenylation
To explore whether cholesterol de¢ciency resulting from
HMG-CoA reductase inhibition might contribute to SOCS-3
induction, we supplied cells with the cholesterol precursor
substrates mevalonate, FPP and GGPP. Results indicated
that in the presence of each substrate, lovastatin- and £uva-
statin-induced SOCS-3 induction was signi¢cantly reduced
(Fig. 4A). At the same concentration (10 WM) tested, the in-
hibition by GGPP was more obvious than FPP. This suggests
that a process mediated by protein isoprenylation might bal-
ance the gene expression of SOCS-3. Interrupting this balance
by statins positively modulates SOCS-3 mRNA level.
Since ERK and p38 MAPK activation have been implicated
Fig. 1. Lovastatin and £uvastatin induced SOCS-3 expression in
RAW264.7 macrophages. RAW264.7 macrophages were incubated
with the indicated concentrations of statin for 24 h (A) or for di¡er-
ent periods (B). In some experiments LPS (0.1 Wg/ml) was added for
3 or 6 h (B). The protein levels of SOCS-3 and L-actin were mea-
sured in the cell lysates by Western blot. The results are representa-
tive of three di¡erent experiments.
Fig. 2. Lovastatin and £uvastatin did not a¡ect SOCS-1, -2, -5, and
-6 expression in RAW264.7 macrophages. RAW264.7 macrophages
were incubated with 30 WM statins for 24 h, or 0.1 Wg/ml LPS for
6 h. Then the protein levels of SOCSs and L-actin were measured in
the cell lysates by Western blot. The results are representative of
three di¡erent experiments.
FEBS 27879 20-11-03
K.-C. Huang et al./FEBS Letters 555 (2003) 385^389386
for SOCS gene expression [12,17,18], we examined the possi-
ble signaling cascades underlying the action of statins. Results
indicated that the upregulation of SOCS-3 by lovastatin and
£uvastatin was not a¡ected by inhibitors of protein kinase C
(PKC) (Ro318220, GF109203X), protein kinase A (PKA)
(KT5720), mitogen-activated protein/ERK kinase (MEK)
(PD98059), p38 MAPK (SB203580), JNK (SP600125), Src
family members (PP2), tyrosine kinases (herbimycin A), Raf
(GW5074), Ras (FPTI), or Rho kinase (Y27632). Neither did
the PKA activator dibutyryl cAMP (100 WM) alter the stim-
ulatory e¡ect of statins (Fig. 4B).
3.3. SOCS-3 induction interrupts cytokine-induced STAT
phosphorylation
To understand the outcome of SOCS-3 induction on STAT
signaling, we examined the signaling events of three cytokines
that activate di¡erent STATs in macrophages. We treated
RAW264.7 macrophages with statin for 24 h, replaced the
culture with fresh medium to wash out statin, and immedi-
ately stimulated cells with IFN-Q, IL-6 or M-CSF. Results
from immunoblotting revealed that in cells expressing large
amounts of SOCS-3 following treatment with lovastatin and
£uvastatin, the phosphorylated forms of STAT-1, STAT-3,
and STAT-5, respectively induced by these cytokines, were
markedly reduced. In contrast, pravastatin-treated cells still
responded to cytokines as control group (Fig. 5). After 24 h
incubation with statins, protein levels of STAT-1, STAT-3
and STAT-5 were not changed. These results indicate that
the upregulation of SOCS-3 functions as a negative regulator
for cytokine signaling.
4. Discussion
It has been established that transcripts encoding SOCSs are
often present in cells at low or undetectable levels, but are
upregulated by a broad spectrum of agonists, including cyto-
kines, hormones, and infectious agents in di¡erent tissues [5].
Fig. 3. Statins induced SOCS-3 expression at the transcriptional lev-
el. RAW264.7 macrophages were incubated with 30 WM statins for
the indicated time periods. Subsequently, total RNA was prepared
and subjected to RT-PCR analysis for SOCS-3 mRNA level. L-Ac-
tin mRNA level was used as the internal control. The SOCS-3
mRNA level, which was measured by densitometry and normalized
to the level of L-actin mRNA, was calculated as a percentage of the
control response without statin treatment.
Fig. 4. Mevalonate and its metabolites reversed SOCS-3 induction by statins. RAW264.7 macrophages were pretreated with vehicle, mevalonate
(100 WM, 1 mM), FPP (1^10 WM), GGPP (1^10 WM) (A), or indicated kinase inhibitors or dibutyryl cAMP (B) at the concentrations indicated
for 30 min. Lovastatin or £uvastatin (each at 10 WM) was then added and incubated for 24 h. Protein levels of SOCS-3 were measured in the
cell lysates by Western blot. The results are representative of three separate experiments.
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Usually the expression of SOCS family members tends to vary
with the cell line studied. The corresponding SOCS proteins
thus play a negative feedback role in cytokine signaling path-
ways and serve as a negative cross-talk between cytokines and
other proin£ammatory stimuli. The signaling of IFN-Q can be
inhibited by both SOCS-1 [3] and SOCS-3 [27], the signaling
of LPS and tumor necrosis factor-K can be inhibited by
SOCS-1 [9^11], while that of IL-6 can be inhibited by
SOCS-3 [13,28,29]. Based on these results, induction of
SOCS is a therapeutic strategy for treating in£ammatory dis-
eases [30]. In this study, we demonstrated a novel anti-in£am-
matory mechanism of statins. We observed that among SOCS
family members examined in murine RAW264.7 macro-
phages, lipophilic statins (lovastatin and £uvastatin) could
induce only SOCS-3 gene expression, which has been recog-
nized to be the most important for regulative e¡ects in im-
mune cells [31]. The lack of e¡ect of pravastatin might be due
to its lower lipid solubility as has been previously shown in
many anti-in£ammatory aspects [26,32,33].
Previous studies have indicated that the anti-in£ammatory
e¡ects of statins result from the depletion of mevalonate prod-
ucts [34]. Our present results indicate that the e¡ect of statins
on SOCS-3 induction might rely on the increased mRNA level
of SOCS-3, and is dependent on the reduction of intracellular
levels of mevalonate products. This implies the possible in-
volvement of a protein isoprenylation-dependent event for
the regulation of SOCS-3 gene expression. To address the
signaling pathway(s) underlying this action of statins, we ex-
amined several pharmacological agents. The concentrations of
kinase inhibitors tested were su⁄cient to inhibit speci¢c tar-
gets by our previous studies in macrophages [35,36]. Present
results excluded the roles of PKC, PKA, Ras/Raf/MEK, p38
MAPK, JNK, Src family members, and Rho kinase. Further-
more, as SOCS can be upregulated by cytokines transducing
STAT signaling pathways [12], we examined this possibility in
the action of statins. In the RAW264.7 macrophage system,
we did not detect any changes of tyrosine-phosphorylated
active forms of STAT-1, STAT-3, STAT-5, and STAT-6 by
statin treatment alone. Moreover, the non-selective tyrosine
kinase inhibitor herbimycin A, which can inhibit JAK activity
and thus interrupt STAT signaling, also did not change the
statin-induced SOCS-3 regulation. Although a recent report
demonstrating SOCS-3 to be an NF-UB-induced gene [37],
this possibility underlying the action of statins seems impos-
sible. This is because our previous study proved the inhibitory
e¡ect of statins on NF-UB activation in macrophages [26]. To
date, the identity of the isoprenylating target and the linkage
between the isoprenylation step and SOCS-3 gene expression
remain unknown.
In this study we also suggest the signaling role of statin-
induced SOCS-3 expression in negative regulation of cytokine
action. However, we found that RAW264.7 cells, which were
primed with statins for 24 h and then washed with fresh me-
dium, had low responsiveness to IFN-Q, IL-6 and M-CSF, in
terms of activation of STAT-1, STAT-3 and STAT-5, respec-
tively. This ¢nding implies the non-speci¢c action of SOCS-3
upregulation to uncouple the signaling pathways of di¡erent
cytokines. This result also provides an explanation to support
previous observations with statins in inhibition of many bio-
logical actions of IFN-Q, such as antigen presentation, T cell
di¡erentiation to the Th1 phenotype, and NOS induction
[21,24,26,38].
Previous studies have reported that macrophages in re-
sponse to LPS are able to release SOCS-inducing cytokines,
such as IFN-K/L and IL-10 [8,16,39]. Moreover, based on
reports showing the ability of IL-1 [17], IL-6 [13,40,41], and
tumor necrosis factor-K [14,42] in SOCS induction, we wonder
whether the action of statins might indirectly result from the
release of cytokines, which then function as autocrines or
paracrines to modulate SOCS-3 expression. Since these cyto-
kines’ production is regulated at the transcriptional level fol-
lowed by the translation step, we treated cells with the protein
synthesis inhibitor cycloheximide, to clear up this possibility.
The data showing no changes of statin-induced increase of
SOCS-3 mRNA level in the presence of cycloheximide ruled
out this possibility (data not shown).
In conclusion, we demonstrated a novel indirect e¡ect of
statins to uncouple JAK-STAT signaling of cytokines through
Fig. 5. Statin-induced SOCS-3 induction inhibited the signaling of
STATs. Cells were treated with vehicle or statins (each at 10 WM)
for 24 h. Culture medium was then washed, and cells were stimu-
lated with IFN-Q (3 ng/ml), M-CSF (30 ng/ml) or IL-6 (10 ng/ml)
for 30 min. Protein levels of STAT-1, STAT-3, STAT-5, and SOCS-
3 were measured in the cell lysates by Western blot. The results are
representative of three separate experiments.
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the induction of SOCS-3. These results suggest that the ca-
pacity of statins to exert anti-in£ammatory action partially
results from the induction of SOCS-3, leading to the down-
modulation of the e¡ector functions of IFN-Q-activated mac-
rophages.
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